INCYTE CORPORATION
NASDAQ: INCY (Incyte Corporation)
Last update: 1 hour ago116.93
3.49 (3.08%)
| Previous Close | 113.44 |
| Open | 113.93 |
| Volume | 2,235,198 |
| Avg. Volume (3M) | 1,650,083 |
| Market Cap | 23,701,446,656 |
| Price / Earnings (TTM) | 14.90 |
| Price / Earnings (Forward) | 14.71 |
| Price / Sales | 4.47 |
| Price / Book | 4.05 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2026 |
| Profit Margin | 0.48% |
| Operating Margin (TTM) | 20.65% |
| Diluted EPS (TTM) | 0.200 |
| Quarterly Revenue Growth (YOY) | 19.50% |
| Quarterly Earnings Growth (YOY) | -6.70% |
| Total Debt/Equity (MRQ) | 1.18% |
| Current Ratio (MRQ) | 2.04 |
| Operating Cash Flow (TTM) | 382.59 M |
| Levered Free Cash Flow (TTM) | 618.05 M |
| Return on Assets (TTM) | 2.04% |
| Return on Equity (TTM) | 0.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Incyte Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | -5.0 |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 0.22 |
Select this tab to load the latest available analysis.
|
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 2.01% |
| % Held by Institutions | 100.65% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2026 | 30,762,330 |
| Dodge & Cox | 30 Jun 2026 | 11,957,326 |
| Aqr Capital Management Llc | 30 Jun 2026 | 5,320,901 |
| Lsv Asset Management | 30 Jun 2026 | 4,123,759 |
| Invesco Ltd. | 30 Jun 2026 | 4,080,461 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CAGNONI PABLO J | - | 113.27 | -2,642 | -299,259 |
| Aggregate Net Quantity | -2,642 | |||
| Aggregate Net Value ($) | -299,259 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 113.27 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CAGNONI PABLO J | Officer | 15 Oct 2026 | Sell (-) | 2,642 | 113.27 | 299,259 |
| CAGNONI PABLO J | Officer | 15 Oct 2026 | Option execute | 2,642 | - | - |
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |